arrow
S

S. Vincent Rajkumar

Mayo Clinic
H指数:165
被引数:13.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biomarkers of cellular senescence and their association with frailty, clinical outcomes, and survival in multiple myeloma

细胞衰老的生物标志物及其与多发性骨髓瘤中虚弱、临床结局和生存期的关联

2026-10-300
OAAI
Spatial profiling of extramedullary multiple myeloma demonstrates immune-excluded and suppressive tumor microenvironment

髓外多发性骨髓瘤的空间分布特征显示其存在免疫排斥和抑制性的肿瘤微环境

2026-10-270
OAAI
Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival

1q染色体增益定义了AL淀粉样变性中一种浆细胞占优势的不良风险亚型,其长期生存率较差

2026-08-260
PRE
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients

达雷木单抗治疗的新诊断多发性骨髓瘤患者中缺铁的高发生率

2026-08-210
PRE
Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma
Leukemia
IF13.4
2026-07-210
PRE
Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

达拉妥单抗、伊沙佐米和来那度胺联合或不联合地塞米松治疗新诊断骨髓瘤的初始疗法

2026-07-180
OA
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma

接受Ciltacabtagene-Autoleucel治疗的复发/难治性多发性骨髓瘤患者的早期治疗失败

2026-06-250
PRE
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

自体干细胞移植治疗多发性骨髓瘤后继发血液系统恶性肿瘤的特征与结局

2026-06-230
OAAI
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia

原发性浆细胞白血病患者首次进展后的进展模式与临床结局

2026-06-030
PRE
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10–49 years of age: a population-based study from the National Health and Nutritional Examination Survey

使用敏感质谱分析法在10-49岁青年人中检测意义未明的单克隆免疫球蛋白病(MGUS)的患病率:一项基于国家健康与营养调查的人口研究

2026-05-250
OAAI
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype

AL型淀粉样变性接受抗浆细胞疗法后肾脏反应的预测因素:基线血清游离轻链水平和轻链亚型的影响

2026-05-100
PRE
Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study

胰岛素样生长因子I(IGF-I)循环水平与多发性骨髓瘤风险:一项观察性和孟德尔随机化研究

2026-03-010
OAAI
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma

诊断时升高的非克隆性骨髓浆细胞分数与多发性骨髓瘤的预后改善相关

2026-01-030
OAAI